The route to an effective antiviral treatment against SARS-CoV-2 has been marked by
dozens of negative clinical trials, with thousands of patients across the globe enrolled in …

The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …

Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Introduction Molnupiravir (MOV) is a broad-spectrum oral antiviral agent approved for the
treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …